Patent intelligence · US
US 8404869
Phenanthrenequinone-based compound and pharmaceutical composition containing the same for the treatment or prevention of disease involving metabolic syndrome
Phenanthrenequinone-based compound and pharmaceutical composition containing the same for the treatment or prevention of disease involving m…
Patent details — US 8404869
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 26, 2013
- Expiration
- Mar 21, 2033
- Applicant
- MAZENCE INC.
- Claims
- 15
- CPC classes
- A61P, A61P1/16, A61P27/02, A61P29/00
Quick answer
US 8404869 (Phenanthrenequinone-based compound and pharmaceutical composition containing the same for the treatment or prevention of disease involving metabolic syndrome) is held by MAZENCE INC.. Status: granted. Granted Mar 26, 2013. Expires Mar 21, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- MAZENCE INC.
- Grant date
- Expiration
- Claims
- 15
- CPC classes
- A61P, A61P1/16, A61P27/02, A61P29/00, A61P3/00, A61P3/04
More from MAZENCE INC.
Related pharmaceutical patents in our USPTO index.
-
US 12310943
Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders
granted -
US 12297182
Compositions comprising an urolithin compound
granted -
US 12226455
Medical composition for treating cardiac wasting and cachexia
granted -
US 12220424
Compositions comprising nicotinamide riboside and a urolithin
granted -
US 12109190
Urolithins as immune response enhancers
granted -
US 12036205
Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders
granted -
US 12030863
Prodrugs of urolithins and uses thereof
granted -
US 11969408
Method for improving mitophagy in subjects
granted
Related coverage
Frequently asked questions
What is US patent 8404869?
US 8404869 (Phenanthrenequinone-based compound and pharmaceutical composition containing the same for the treatment or prevention of disease involving metabolic syndrome) is held by MAZENCE INC.. Status: granted. Granted Mar 26, 2013. Expires Mar 21, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8404869?
MAZENCE INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 60 pharmaceutical patents for this assignee.
When does US 8404869 expire?
Our index shows an expiration date of Mar 21, 2033 (7 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.